PD1 blockade enhances K(+) channel activity, Ca(2+) signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer

BACKGROUND: Immunotherapy has emerged as a promising treatment modality for head and neck squamous cell carcinoma (HNSCC). Pembrolizumab, an anti-programmed death 1 antibody, is an immunotherapy agent currently approved for metastatic HNSCC and curative intent clinical trials. Although clinical resp...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Newton, Hannah S, Gawali, Vaibhavkumar S, Chimote, Ameet A, Lehn, Maria A, Palackdharry, Sarah M, Hinrichs, Benjamin H, Jandarov, Roman, Hildeman, David, Janssen, Edith M, Wise-Draper, Trisha M, Conforti, Laura
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7566435/
https://ncbi.nlm.nih.gov/pubmed/33060146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000844
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares